Rezolute (RZLT) Amortization of Deferred Charges (2012 - 2019)

Rezolute recorded quarterly Amortization of Deferred Charges of $472000.0 in Q1 2019, down 46.24% quarter-over-quarter from $878000.0 in Q4 2018.

Rezolute's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $472000.0 for Q1 2019.

  • In Q1 2019, Amortization of Deferred Charges changed N/A year-over-year to $472000.0; the TTM figure through Dec 2019 stood at $472000.0 (down 70.15% YoY), while the FY2019 annual figure was $2.1 million, changed N/A from the prior year.
  • Amortization of Deferred Charges came in at $472000.0 for Q1 2019 at Rezolute, down from $878000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $878000.0 in Q4 2018 to a low of $472000.0 in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Rezolute 374.41 Mn 374.41 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2019 472,000.00
Mar 31, 2019 472,000.00
Dec 31, 2018 878,000.00
Dec 31, 2018 878,000.00
Sep 30, 2018 703,000.00
Sep 30, 2018 703,000.00
Mar 31, 2014 266,693.00
Mar 31, 2014 266,693.00
Dec 31, 2013 74,136.00
Dec 31, 2013 74,136.00
Sep 30, 2013 75,508.00
Sep 30, 2013 75,508.00
Jun 30, 2013 90,585.00
Jun 30, 2013 90,585.00
Mar 31, 2013 101,082.00
Mar 31, 2013 101,082.00
Dec 31, 2012 42,643.00
Dec 31, 2012 42,643.00
Sep 30, 2012 44,786.00
Sep 30, 2012 44,786.00
Jun 30, 2012 59,021.00
Jun 30, 2012 59,021.00
Mar 31, 2012 47,833.00
Mar 31, 2012 47,833.00